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ABSTRACT
It is becoming apparent that a number of pathogenic mecha-
nisms contribute to diabetic neuropathy, so that therapeutic
interventions that target one particular mechanism may have
limited success. A recently published preclinical study has
adopted an alternative approach by using a novel small
molecule to induce heat-shock protein 70. This confers upon
neurons, and perhaps other cells of the nervous system, the
ability to better tolerate the diverse stresses associated with
diabetes rather than intervening in their production.
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The increasing incidence of diabetes is placing ever-greater
demands on health care systems. Not only does the disease
lower life expectancy by 10–15 years, but quality-of-life is also
impaired by progressive damage to the cardiovascular system,
kidneys, eyes and nerves. These secondary complications of
diabetes result from a combination of impaired insulin
signalling, hyperglycaemia and dyslipidaemia, and ameliorat-
ing their physical and psychological consequences contributes
significantly to the estimated $174 billion in yearly costs that
have been attributed to diabetes in the US alone (http://
www.cdc.gov/diabetes/pubs/factsheet07.htm; Centers for
Disease Control 2007). Diabetic neuropathy is the most
common of the complications of diabetes, with nerve damage
developing in over 50% of all diabetic patients. Long-term
studies have demonstrated that improving glycaemic control
canslowonsetandprogressionofneuropathy,butalsosuggest
that hyperglycaemia is notthe sole pathogenic factor involved,
and that reversing established nerve damage is particularly
difficult to achieve (Writing Team for the Diabetes Control and
Complications Trial/Epidemiology of Diabetes Interventions
and Complications Research Group, 2002). There is no FDA
(Food and Drug Administration) approved drug for diabetic
neuropathy and improved glycaemic control is the standard
of care in most countries. Achieving tight glycaemic control
by conventional means, such as insulin injections or pump
delivery, diet control and glucose-modulating drugs, remains
challenging for physician and patient alike. Recognizing that
the means of achieving perfect glycaemic control for all
diabetic patients is not yet at hand, many investigators have
adopted a parallel approach that seeks to indentify the
pathogenic cascades that flow downstream from insulinopae-
nia and hyperglycaemia in the hope of discovering alternative
sites for therapeutic intervention. It may be fair to say that
there has been much scientific progress in this regard over the
last 40 years, but no clinical breakthrough.
The paper recently presented in ASN NEURO by Urban et al.
(2010) reports an unusual approach to identifying a potential
therapy for diabetic neuropathy. The authors have used the
emerging appreciation of the roles of HSPs (heat-shock pro-
teins) in cellular stress and survival pathways to identify an
agent that does not rely on targeting a specific pathogenic
mechanism, but rather manipulates the capacity of cells
to tolerate otherwise toxic stresses. Specifically, they report
the characteristics of KU-32, a small molecule based on
novobiocin, which inhibits HSP90, thereby inducing neuro-
protective HSP70. The authors go on to test the capacity
of HSP70 induction to protect cells of the nervous system
from exogenous stressors. It is particularly noteworthy that
the study treads carefully through the minefield that is the
modelling of diabetic neuropathy by using a diverse col-
lection of assays that range from acute glucotoxicity directed
at embryonic sensory neurons in culture, to phenotyping of
sensory and motor nerve dysfunction in Type 1 diabetic mice.
Efficacy of KU-32 in a mouse model of diabetic neuropathy
is demonstrated by intervention against established indices of
nerve dysfunction. This contrasts with most preclinical
studies, which tend to report the ability of a therapy to
prevent onset of neuropathy – a design that equates to a
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diabetes. Such clinical trials are viable and any drug shown
to be effective would have great commercial potential, as it
would require all diabetic patients to take the drug from
diagnosis of the disease for life. However, prevention studies
can be prohibitively expensive, as they require large
populations of patients to be followed over many years due
to the unpredictable incidence and progression of diabetic
neuropathy. By using an intervention paradigm, the authors
have set a higher bar for success, as it is not clear that all
indices of neuropathy may be amenable to reversal once
established. However, preclinical success offers the potential
of a more practical design for future clinical trials, in which
smaller cohorts of patients with measurable neuropathy can
be used to assess subsequent recovery.
Urban et al. (2010) use the intervention paradigm to show
that KU-32 is effective against a number of indices of
peripheral neuropathy. Behavioural tests of nocifensive
responses to sensory stimuli are particularly amenable to
these studies, as they allow iterative testing to identify onset
of a disorder and subsequent responses to drug intervention.
It is also tempting to extrapolate impaired nociception in
these tests to the sensory loss reported by most patients with
diabetic neuropathy. All such behavioural studies in rodents
carry the caveat that depressed nocifensive responses can
reflect disruption of sensory input, central processing or effec-
tor systems, although the frequent concern that impaired
responses in diabetic animals are caused by the cachexia that
accompanies Type 1 diabetes are offset in the present study by
noting that KU-32 did not alter any systemic indicators of
diabetes, such as hyperglycaemia or weight loss (Table 1 in
Urban et al., 2010). Interestingly, both the presence of ther-
mal hypoalgesia in untreated diabetic mice and the reversal of
hypoalgesia by KU-32 occur in the absence of loss of IENF
(intra-epidermal nerve fibres), whichincludetheheat-sensitive
C fibres. Loss of IENF is frequently reported in diabetic patients
and rodents, and quantification of IENF in skin biopsies is being
developed as a measure of small fibre neuropathy (Lauria et al.,
2010). However, thermal hypoalgesia precedes detectable IENF
loss in diabetic mice (Beiswenger et al., 2008) and the present
data set further emphasizes that other mechanisms may also
be involved. It takes 3–4 weeks of treatment with KU-32
treatment to reverse loss of sensation to tactile and thermal
stimuli (Figure 5 in Urban et al., 2010), which is consistent with
the time course of action of another HSP70 inducer in a model
of physical nerve injury (Kalmar et al., 2003) and might argue
against an acute neurochemical mechanism of action. The
impactofKU-32 onotherdiabetes-induced changestosensory
neurons that could contribute to loss of sensory function,
such as impaired synthesis, axonal transport and release of
neuropeptides may warrant investigation.
KU-32 also shows efficacy against MNCV (motor nerve
conduction velocity) slowing. The ability to prevent or reverse
MNCV slowing in diabetic rodents has historically been the gold
standardfor demonstratingtherapeutic potentialoftreatments
for diabetic neuropathy, as diabetic patients show a similar
slowing of large fibre conduction early in their disease that is
predictive of future degenerative neuropathy. However, the
literature now contains hundreds of diverse treatments that
have ameliorated conduction slowing in diabetic rodents, with-
out ever progressing to clinical use, and this plethora of false
positives has somewhat tarnished the gold. In part, this may be
because conduction slowing in clinical diabetic neuropathy
involves pathogenic components that are not present in most
rodent models of diabetes, such as segmental demyelination.
Indeed, the lack of pathological damage to Schwann cells is a
significant failing of most rodent models of diabetic neuro-
pathy. The use of neuregulin-mediated demyelination in a
neuron–Schwann cell co-culture system (Figure 3 in Urban
et al., 2010) is a creative approach to circumnavigating the
limitations of current animal models, and the efficacy of
KU-32 in preventing demyelination adds another facet to its
therapeutic potential. Although no single demonstration of
efficacy in model systems can guarantee clinical success, the
cumulative evidence offered in the paper by Urban et al. (2010)
using diverse assays makes a relatively compelling case for the
viability of KU-32 as a potential therapeutic.
The challenge for development of KU-32 is where to go
next. Dose range and long-term toxicity issues clearly need to
be addressed for a drug treatment approach that patients
would be required to adopt for the rest of their lives. The use
of HSP70-deficient mice to confirm involvement of this
protein in the mechanism of action of KU-32 (Figure 6 in
Urban et al., 2010) is elegant and the authors note that
extension of mechanistic studies, particularly to identify the
downstream consequences of HSP70 induction and the cell
types in which it occurs after systemic administration of KU-
32, will provide valuable information. The efficacy of KU-32
against diverse functional disorders encourages optimism for
success against symptomatic neuropathy, which represents
the target currently set by many regulatory agencies. How-
ever, diabetic neuropathy is a degenerative disease and, as
mentioned above, most animal models show limited degen-
erative changes. Studies in diabetic animals that develop IENF
loss may be of value, as this is a feature of both experimental
and clinical diabetic neuropathy and few agents have yet
been reported that restore IENF density in a reversal
paradigm. The authors also speculate that KU-32 may have
the potential to ameliorate aspects of painful diabetic
neuropathy and indeed induction of HSP70 has previously
been shown to ameliorate allodynia in a model of neuro-
pathic pain induced by physical nerve injury (Kalmar et al.,
2003). Studies in animal models of diabetes that show
allodynia and hyperalgesia are clearly warranted.
Thecostofclinicaltrialsagainstdegenerativeneuropathyisa
major obstacle to drug development for all but the largest
companies. Success in alleviating pain may facilitate a faster
track to clinical use, due to the shorter duration of clinical trials
andbecausethe templatefor achieving regulatoryapproval has
already been established by drugs that suppress pain without
preventing the underlying degenerative neuropathy. A therapy
that treats both the pain and neurodegeneration of diabetic
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long-term benefit to patients. By manipulating cellular
tolerance of stress, KU-32 may highlight a therapeutic
approach more suited to addressing the diverse pathogenic
mechanisms that contribute to diabetic neuropathy than
attempts to intervene against any particular mechanism.
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